Enveric Biosciences, Inc. (ENVB): R&D Expense
$2.78M
Year ended 2025-12-31
$2.48M
Trailing 12 months to 2026-06-30
-29.8%
3-year compound annual growth
+74.1%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.78M | -2.1% | 2026-03-27, From 2025-01-01 |
| 2024-12-31 | $2.84M | -60.8% | 2026-03-27, From 2024-01-01 |
| 2023-12-31 | $7.25M | -9.7% | 2025-03-28, From 2023-01-01 |
| 2022-12-31 | $8.03M | +67.6% | 2024-03-26, From 2022-01-01 |
| 2021-12-31 | $4.79M | n/m | 2023-06-09, From 2021-01-01 |
| 2020-12-31 | $174.1K | n/a | 2022-03-31, From 2020-01-01 |
| No annual figure between 2016-12-31 and 2020-12-31. | |||
| 2016-12-31 | $55.1K | n/a | 2017-04-04, From 2016-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | 2025-12-31 | $2.78M | -2.1% |
| Petros Pharmaceuticals, Inc. (PTPI) | 2024-12-31 | $2.62M | +8.5% |
| Azitra, Inc. (AZTR) | 2025-12-31 | $4.84M | +2.4% |
| Polaryx Therapeutics, Inc. (PLYX) | 2025-12-31 | $6.27M | +122.9% |
| Quantum Cyber N.V. (QUCY) | 2025-12-31 | $4.91M | -14.2% |
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | 2025-12-31 | $2.11M | -57.8% |
| International Stem Cell Corp (ISCO) | 2025-12-31 | $684.0K | +4.1% |
| AEON Biopharma, Inc. (AEON) | 2025-12-31 | $4.09M | -71.1% |
| Jupiter Neurosciences, Inc. (JUNS) | 2025-12-31 | $2.09M | +323.5% |
Compare ENVB, PTPI, AZTR, PLYX side by side · Screen every company in Pharmaceutical Preparations ↗